GlassScriptPhysician profile
Michael William Lievens
NPI 1225038029
$1,474.69
in general payments reported to CMS, 2019-2025
17 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $133 · 2021: $63.81 · 2022: $251 · 2023: $81.38 · 2024: $228 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.52 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.82 | 2021-2025 | |
| Janssen Biotech, INC. | $211.51 | 2019-2022 | |
| Pfizer INC. | $191.80 | 2022-2025 | |
| Medtronic, INC. | $127.92 | 2025 | Endoflip |
| Medtronic USA, INC. | $99.78 | 2019 | |
| Eli Lilly and Company | $80.80 | 2020 | |
| Gilead Sciences, INC. | $78.95 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $42.93 | 2024-2025 | Givlaari |
| Celltrion USA INC. | $34.31 | 2025 | Vegzelma |
| Lilly USA, LLC | $32.21 | 2024 | Omvoh |
| Celgene Corporation | $27.20 | 2022-2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $20.16 | 2024 | Edgehog |
| Ferring Pharmaceuticals INC. | $19.61 | 2025 | Rebyota |
| Amgen INC. | $19.39 | 2023 | Amjevita, Avsola |
| Sandoz INC. | $14.61 | 2024 | Hyrimoz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lievens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.